Introduction
Hepatitis B is a chronic liver disease caused by hepatotrophic hepatitis B virus (HBV) infection. Approximately 2 billion people worldwide are exposed to HBV and more than 350 million people are chronically infected therewith.
1 HBV is also a major cause of cirrhosis and hepatocellular carcinoma (HCC). The prevalence of HBV infection worldwide differs among geographic areas, and proportions of carriers vary from 0.1% to 15%. In Korea, HBV infections have gradually decreased since commercialization of the hepatitis B vaccine (1990s), although 3.7% of the population is still infected.
The goal of chronic hepatitis B (CHB) treatment is to suppress the proliferation of HBV. By inhibiting HBV proliferation, inflammation is relieved, and fibrosis, cirrhosis, liver failure, or HCC can be prevented. Thereby, it is possible to reduce mortality due to liver disease and to improve the survival rate thereof. 5 Although the ideal treatment goal is loss of hepatitis B surface antigen (HBsAg), complete treatment of HBV is almost impossible, because nuclear covalently closed circular DNA (cccDNA) remains after treatment. In clinical practice, alanine aminotransferase (ALT) normalization, nondetection of serum HBV DNA, serum hepatitis B e antigen (HBeAg) loss or seroconversion, and histologic improvement are used as treatment response indicators. 6 Entecavir (ETV) is a deoxyguanosine nucleoside analog that is converted to its active form, ETV-triphosphate, in vivo. ETV-triphosphate exerts antiviral effects by inhibiting three steps of replication: priming of HBV DNA polymerase, reverse transcription of the HBV DNA negative strand from pregenomic mRNA, and synthesis of the HBV DNA positive strand. 7, 8 In a Phase III clinical trial, ETV was shown to be superior to lamivudine in terms of histologic improvement, reduction of HBV DNA levels from baseline, proportion of patients with undetectable HBV DNA, and ALT normalization. 9, 10 ETV is now widely used as a standard therapeutic agent for CHB and is recommended as a first-line treatment by international and domestic guidelines, including the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), Asian Pacific Association for the Study of the Liver (APASL), and Korean Association for the Study of the Liver (KASL). 6, 11, 12 Baracle ® is a ETV product developed by Dong-A ST based on a pharmacokinetic profile equivalent to ETV from BMS in bioequivalence tests. However, studies have yet to demonstrate the efficacy and safety of ETV from Dong-A ST in comparison with ETV from BMS for CHB patients. Therefore, the current study was designed to compare the antiviral efficacy and safety between ETV from Dong-A ST (Baracle) and ETV from BMS (Baraclude ® ) in patients with CHB.
Patients and methods study design
This study was conducted as a multicenter, double-blind, active-controlled, randomized with stratification, parallel group, and comparative trial at 18 sites in South Korea from September 2013 to November 2015. As patients with HBeAg positivity or negativity may differ in their responses to antiviral therapy, a stratified randomization was performed to ensure balance between treatment groups.
All subjects who consented to participate in the present trial provided written informed consent and were subjected to screening tests. Within 4 weeks after screening, subjects who were determined to be eligible for the study were randomized with stratification 1:1 to Baracle (ETV 0.5 mg; Dong-A ST Co., Seoul, Republic of Korea) or Baraclude (ETV 0.5 mg; Bristol-Myers Squibb Korea) treatment groups based on HBeAg status (positive/negative). After stratified randomization, subjects were administered either ETV from Dong-A ST or ETV from BMS via one tablet once daily on an empty stomach (2 hours after taking meal or at least 2 hours before taking meal). Each subject took the investigational products (IP) for 48 weeks, during which the subjects visited the clinical trial institution according to the schedule specified in the study protocol, to receive the planned efficacy and safety assessments.
Patients
Inclusion criteria were male and female patients of ages 18-65 years who were diagnosed as HBsAg-positive at the screening visit and had a medical record of CHB for at least 6 months. For those who were diagnosed as HBeAg-positive at the screening visit, HBV DNA levels were $1×10 5 copies/mL, which was quantified through real-time PCR, and for those who were diagnosed as HBeAgnegative, HBV DNA levels were $1×10 4 copies/mL. Subjects were to have ALT levels between 2 times and 10 times the upper limit of the normal (ULN) levels at the screening visit. Subjects with compensated cirrhosis were eligible for the study if their ALT levels were between the ULN and 10 times the ULN levels. Subjects were not administered any antiviral agents, including interferon or pegylated interferon agents, for at least 12 weeks and within 24 weeks prior to screening.
Exclusion criteria included infection with hepatitis C virus (HCV), hepatitis D virus (HDV), human immunodeficiency virus (HIV), decompensated diseases, hematochromatosis, Wilson's disease, alcoholic liver disease, autoimmune liver disease, and α-1 antitrypsin deficiency. Subjects who were administered immunosuppressive agents or systemic corticosteroids for more than 4 weeks within 24 weeks prior to screening were excluded. Subjects with less than 50 mL/min of creatinine clearance (body weight and age were adjusted by the Cockgraft-Gault method) at the screening visit or subjects with greater than 50 mL/min of α-fetoprotein at the screening visit, who were presumed to have HCC based on the result of the relevant imaging test, were also excluded. The primary efficacy endpoint was virologic improvement, defined as a change in HBV DNA level (log 10 ) from baseline to week 24 after IP administration. Secondary efficacy endpoints included virologic endpoints (the proportion of subjects whose HBV DNA levels were less than 300 copies/mL at week 24 and week 48, change in HBV DNA levels [log 10 ] from baseline to week 48), biochemical endpoints (the proportion of subjects whose ALT levels become normal at week 24 and week 48, the proportion of subjects whose HBV DNA levels were less than 300 copies/mL and whose ALT levels became normal at week 48), and serologic endpoints (the proportion of subjects who were HBeAg-positive at the screening visit, but lost HBeAg at week 24 and week 48; the proportion of subjects who were HBeAg-positive at the screening visit, but showed HBeAg seroconversion at week 24 and week 48; the proportion of subjects who showed loss of HBsAg and emergence of anti-HBs at week 48).
The tertiary efficacy endpoint was the proportion of subjects who expressed HBV DNA gene mutations after IP administration, which was confirmed by HBV DNA sequencing.
safety
Adverse events, such as subjective and objective symptoms, and abnormalities in clinical laboratory tests and vital signs, were assessed. The number and percentage of subjects who experienced ALT flare ($10X ULN and $2X baseline) were also assessed.
statistical analysis
All efficacy analyses were performed on the full analysis set (FAS) and per-protocol set (PPS). The FAS population included all randomized subjects who received at least one dose of the study drug and had at least one valid post-baseline efficacy evaluation. The PPS population was defined as a subset of the FAS population who completed the study without any major protocol violations.
Assuming a one-sided α level of 0.025 and 80% power, a sample size of 92 patients was estimated with a noninferiority margin of 1. Considering a 20% drop-out rate, the study required a total of 116 patients. For the primary efficacy endpoint, the noninferiority of ETV from Dong-A ST to ETV from BMS was to be supported if the upper limit of the two-sided 95% CI (equivalent to one-sided 97.5% CI) was below the prespecified noninferiority margin of 1. 9, 10, 13, 14 Other secondary and tertiary efficacy endpoints were compared between the two treatment groups using CochranMantel-Haenszel test adjusted for a stratification factor, HBeAg (positive/negative), respectively. Differences in the HBV DNA levels (log 10 ) from baseline to week 48 between the two treatment groups were analyzed using ANCOVA with HBeAg (positive/negative) as a stratification factor.
The number (N) and proportion (%) of subjects who lost HBeAg at week 24 and week 48 were compared between the two treatment groups using χ 2 test or Fisher's exact test. The difference between the two groups with respect to the incidences of adverse events (AEs), adverse drug reactions (ADRs), serious adverse events (SAEs), and serious adverse drug reactions (SADRs) was analyzed using χ 2 test of Fisher's exact test. The number (N) and proportion (%) of subjects with ALT flare ($10X ULN and $2X baseline) were compared using χ 2 test or Fisher's exact test to determine if there was a statistically significant difference between the two groups.
All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). 
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Results
Baseline characteristics
The mean age of the included patients was 45.8±11.0 years, and male sex was predominant (67.8%). The mean prevalent Drug Design, Development and Therapy 2017:11 submit your manuscript | www.dovepress.com
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Kim et al period of CHB was 11.4±10.8 years, and all patients were treatment-naïve. Forty-seven (39.8%) patients had compensated cirrhosis, and the rate of HBeAg positivity was 59.3%. HBV genotype was C in all patients. There was no significant difference in the baseline characteristics between the ETV from Dong-A ST and ETV from BMS treatment groups (Table 1) .
comparison of hBV Dna declines at weeks 24 and 48
Serum HBV DNA levels declined equally at 24 and 48 weeks in both groups. Using the full analysis set, at week 24, the declines in HBV DNA levels from baseline were 4.79 log 10 in ETV from Dong-A ST and 4.64 log 10 in ETV from BMS group. In ANCOVA analysis with HBeAg as a covariate, which was also a stratification factor, HBV DNA declines from baseline to week 24 were 4.81 log 10 in ETV from Dong-A ST and 4.63 log 10 in ETV from BMS group. Regarding the differences in HBV decline, the upper limit of two-sided 95% CI (ie, 97.5% one-sided CI) was 0.208, which is less than the noninferiority margin of 1. At week 48, the covariate analysis with HBeAg as a covariate also revealed that HBV DNA decline was not significantly different between the two groups (P=0.6440): 5.0 log 10 in ETV from Dong-A ST and 4.9 log 10 in ETV from BMS group ( Table 2) .
Proportion of patients with hBV Dna levels ,300 copies/ml at week 48 Figure 1 shows the mean decreases of serum HBV DNA levels during the study period in patients who received either ETV from Dong-A ST or ETV from BMS. There was no significant difference in HBV decline between the two groups during the entire study period. At week 24, 36 (66.7%) patients in ETV from Dong-A ST and 31 (50.0%) in ETV from BMS group achieved HBV DNA less than 300 copies/mL. At week 48, 44 (81.5%) patients in the ETV from Dong-A ST group and 44 (71.0%) in the ETV from BMS group achieved HBV DNA levels less than 300 copies/mL. After adjustment of HBeAg status, we found no significant difference in the proportion of patients with HBV DNA ,300 copies/mL at both weeks 24 and 48 (respectively, P=0.0530 and P=0.2128) (Figure 2 ).
alT normalization and hBeag loss
For all included patients, the rates of ALT normalization were 79.6% in the ETV from Dong-A ST group and 74.2% in the 3 ETV from BMS group at week 24, which was not statistically different (P=0.5131). At week 48, the rates were 77.8% in the ETV from Dong-A ST group and 77.4% in the ETV from BMS group (P=0.9851) (Figure 3 
adverse events
All adverse events were presented after standardization into system organ classes (SOC) and preferred terms (PT) using MedDRA (Version 16.0) ( Table 3 ). There was a total of 47 adverse events (AE; Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment) from 24 (43.6%) patients in the ETV from Dong-A ST group and 73 AEs from 31 (50.0%) patients in the ETV from BMS group (P=0.4912). Mild, moderate, and severe AEs occurred in 37, 8, and 2 cases in the ETV from Dong-A ST group and in 62, 9, and 2 cases in the ETV from BMS group. Adverse drug reactions (ADRs; All noxious and unintended responses to a medicinal product related to any dose) were observed in one case in the ETV from Dong-A ST group and two cases (from 1 patient) in the ETV from BMS group. There were 
Discussion
CHB imposes a significant global health care burden; approximately 5% of individuals throughout the world are estimated to be infected with HBV, and the annual mortality associated with persistent HBV infection is about 1.2 million. 15 International guidelines recommend ETV together with tenofovir (TDF) as the first-line therapy in the treatment of naïve CHB patients because of its potent antiviral activity and higher genetic barrier. 9, 10, 12 Continuous suppression of HBV replication is clinically important as the risk of cirrhosis and/or HCC in CHB patients increases proportionally with increases in serum HBV DNA concentrations. 16, 17 Indeed, since the introduction of ETV in clinical practice, there have been many studies showing the long-term clinical benefits of ETV in terms of prevention of CHB progression (ie, cirrhosis or HCC). 18, 19 In the current study, we observed no differences in suppression of HBV replication and safety between those taking ETV from Dong-A ST and ETV from BMS. The change in HBV DNA levels (log 10 ) from baseline to week 24, which was the primary endpoint of study, was 4.81 log 10 in ETV from Dong-A ST and 4.63 log 10 in ETV from BMS group, confirming that ETV from Dong-A ST is not inferior to ETV 
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Kim et al from BMS. At week 48, declines in HBV DNA were also not significantly different between the two groups (P=0.6440): 5.0 log 10 in the ETV from Dong-A ST and 4.9 log 10 in the ETV from BMS group. The proportions of patients with HBV DNA ,300 copies/mL at weeks 24 and 48 were also not different between the two groups (66.7% vs 50.0% at week 24, 81.5% vs 71.0% at week 48). Thus, the overall antiviral activity was deemed to be comparable between ETV from Dong-A ST and ETV from BMS. In particular, the rates of undetectable serum HBV DNA levels in the present study were similar with ETV pivotal clinical trials, wherein the rates were 67% in HBeAg-positive patients and 90% in HBeAg-negative patients. 9, 10 Because of relatively short treatment period of 1 year, the rates of HBeAg loss might not be fully evaluated or compared in HBeAg-positive patients. Nonetheless, the HBeAg loss rates at week 48 were not different between two groups: 9.7% in ETV from Dong-A ST and 8.3% in ETV from BMS group.
A major concern regarding generic antiviral agent for HBV infection would be whether it can show bioequivalence, comparable efficacy, and safety in real patients. First, ETV from Dong-A ST demonstrated an equivalent pharmacokinetic profile to ETV from BMS in bioequivalence tests. When ETV from Dong-A ST or ETV from BMS 0.5 mg Tab was administered in 36 healthy male adults, the two-sided 90% CI of C max and AUC t were 1.0366-1.1740 and 0.9605-1.1149, respectively. Thus, it was confirmed that they were within the acceptable bioequivalence range of 0.80-1.25. Second, in this multicenter, prospective randomized trial, antiviral potency indicated by serum HBV DNA declines at weeks 24 (primary endpoint) and 48 (secondary endpoint) and the proportions of patients with HBV DNA ,300 copies/mL (secondary endpoint) were not different between the two drugs. Lastly, there was a similar safety profile in the ETV from Dong-A ST and ETV from BMS groups. Most of adverse events were mild, and there were rare ADRs or SAEs. In addition, there was no case of SADR. In particular, ETV is known not to be related to nephrotoxicity or loss of bone density. In our study, both ETV from Dong-A ST and from BMS did not result in elevation of serum creatinine or decrease of glomerular filtration rate (GFR) during study period (data not shown).
Although regulation authority does not request a manufacturer to conduct clinical trials to approve a generic drug, data comparing efficacy and safety between generic and branded drugs are sometimes necessary. This is because, in a survey, 25% of physicians stated that they would only increase prescribing generic drugs if additional clinical trials were presented. 20 This study has a strength in that efficacy and safety were compared between original and generic anti-HBV drugs by a well-designed randomized trial. This is the first report to show the comparable efficacy and safety of generic anti-HBV drug. A limitation of this study is a relative short (1 year) duration of drug administration, which may not allow for the comparison of long-term virologic and/or biochemical responses between the two drugs.
Conclusion
In conclusion, we demonstrated that ETV from Dong-A ST is not inferior to ETV from BMS in treatment-naïve HBeAg Drug Design, Development and Therapy
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